Literature DB >> 28463232

Bispecific antibody targets multiple Pseudomonas aeruginosa evasion mechanisms in the lung vasculature.

Ajitha Thanabalasuriar1, Bas Gj Surewaard1, Michelle E Willson1, Arpan S Neupane1, Charles K Stover2, Paul Warrener2, George Wilson2, Ashley E Keller2, Bret R Sellman2, Antonio DiGiandomenico2, Paul Kubes1.   

Abstract

Pseudomonas aeruginosa is a major cause of severe infections that lead to bacteremia and high patient mortality. P. aeruginosa has evolved numerous evasion and subversion mechanisms that work in concert to overcome immune recognition and effector functions in hospitalized and immunosuppressed individuals. Here, we have used multilaser spinning-disk intravital microscopy to monitor the blood-borne stage in a murine bacteremic model of P. aeruginosa infection. P. aeruginosa adhered avidly to lung vasculature, where patrolling neutrophils and other immune cells were virtually blind to the pathogen's presence. This cloaking phenomenon was attributed to expression of Psl exopolysaccharide. Although an anti-Psl mAb activated complement and enhanced neutrophil recognition of P. aeruginosa, neutrophil-mediated clearance of the pathogen was suboptimal owing to a second subversion mechanism, namely the type 3 secretion (T3S) injectisome. Indeed, T3S prevented phagosome acidification and resisted killing inside these compartments. Antibody-mediated inhibition of the T3S protein PcrV did not enhance bacterial phagocytosis but did enhance killing of the few bacteria ingested by neutrophils. A bispecific mAb targeting both Psl and PcrV enhanced neutrophil uptake of P. aeruginosa and also greatly increased inhibition of T3S function, allowing for phagosome acidification and bacterial killing. These data highlight the need to block multiple evasion and subversion mechanisms in tandem to kill P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28463232      PMCID: PMC5451222          DOI: 10.1172/JCI89652

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.

Authors:  Cheol-In Kang; Sung-Han Kim; Hong-Bin Kim; Sang-Won Park; Young-Ju Choe; Myoung-Don Oh; Eui-Chong Kim; Kang-Won Choe
Journal:  Clin Infect Dis       Date:  2003-08-23       Impact factor: 9.079

Review 2.  Ventilator-associated pneumonia caused by ESKAPE organisms: cause, clinical features, and management.

Authors:  Alberto Sandiumenge; Jordi Rello
Journal:  Curr Opin Pulm Med       Date:  2012-05       Impact factor: 3.155

Review 3.  Emerging resistant Gram-negative aerobic bacilli in hospital-acquired infections.

Authors:  Anjali N Kunz; Itzhak Brook
Journal:  Chemotherapy       Date:  2010-11-24       Impact factor: 2.544

Review 4.  Bacterial Extracellular Polysaccharides in Biofilm Formation and Function.

Authors:  Dominique H Limoli; Christopher J Jones; Daniel J Wozniak
Journal:  Microbiol Spectr       Date:  2015-06

Review 5.  Chemical inhibitors of the type three secretion system: disarming bacterial pathogens.

Authors:  Miles C Duncan; Roger G Linington; Victoria Auerbuch
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

6.  Small broad-host-range gentamycin resistance gene cassettes for site-specific insertion and deletion mutagenesis.

Authors:  H D Schweizer
Journal:  Biotechniques       Date:  1993-11       Impact factor: 1.993

Review 7.  Pseudomonas aeruginosa: new insights into pathogenesis and host defenses.

Authors:  Shaan L Gellatly; Robert E W Hancock
Journal:  Pathog Dis       Date:  2013-03-15       Impact factor: 3.166

8.  Role of the type III secreted exoenzymes S, T, and Y in systemic spread of Pseudomonas aeruginosa PAO1 in vivo.

Authors:  Russell E Vance; Arne Rietsch; John J Mekalanos
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

9.  A broad-host-range Flp-FRT recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked Pseudomonas aeruginosa mutants.

Authors:  T T Hoang; R R Karkhoff-Schweizer; A J Kutchma; H P Schweizer
Journal:  Gene       Date:  1998-05-28       Impact factor: 3.688

Review 10.  Structure and function of the Type III secretion system of Pseudomonas aeruginosa.

Authors:  Marlies Galle; Isabelle Carpentier; Rudi Beyaert
Journal:  Curr Protein Pept Sci       Date:  2012-12       Impact factor: 3.272

View more
  37 in total

Review 1.  Mechanisms and Targeted Therapies for Pseudomonas aeruginosa Lung Infection.

Authors:  Colleen S Curran; Thomas Bolig; Parizad Torabi-Parizi
Journal:  Am J Respir Crit Care Med       Date:  2018-03-15       Impact factor: 21.405

2.  ASC acts in a caspase-1-independent manner to worsen acute pneumonia caused by Pseudomonas aeruginosa.

Authors:  A J Hughes; C A Knoten; A R Morris; A R Hauser
Journal:  J Med Microbiol       Date:  2018-06-29       Impact factor: 2.472

3.  Enhancing IgG distribution to lung mucosal tissue improves protective effect of anti-Pseudomonas aeruginosa antibodies.

Authors:  M Jack Borrok; Antonio DiGiandomenico; Nurten Beyaz; Gabriela M Marchetti; Arnita S Barnes; Kristen J Lekstrom; Sandrina S Phipps; Michael P McCarthy; Herren Wu; William F Dall'Acqua; Ping Tsui; Ruchi Gupta
Journal:  JCI Insight       Date:  2018-06-21

4.  Impact of Type III Secretion Effectors and of Phenoxyacetamide Inhibitors of Type III Secretion on Abscess Formation in a Mouse Model of Pseudomonas aeruginosa Infection.

Authors:  Bryan J Berube; Katherine R Murphy; Matthew C Torhan; Nicholas O Bowlin; John D Williams; Terry L Bowlin; Donald T Moir; Alan R Hauser
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

5.  Engineering therapeutic antibodies to combat infectious diseases.

Authors:  Ellen K Wagner; Jennifer A Maynard
Journal:  Curr Opin Chem Eng       Date:  2018-03-07       Impact factor: 5.163

Review 6.  Molecular Mechanisms Involved in Pseudomonas aeruginosa Bacteremia.

Authors:  Stéphane Pont; Manon Janet-Maitre; Eric Faudry; François Cretin; Ina Attrée
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

7.  α-Toxin Induces Platelet Aggregation and Liver Injury during Staphylococcus aureus Sepsis.

Authors:  Bas G J Surewaard; Ajitha Thanabalasuriar; Zhutian Zeng; Christine Tkaczyk; Taylor S Cohen; Bart W Bardoel; Selina K Jorch; Carsten Deppermann; Juliane Bubeck Wardenburg; Rachelle P Davis; Craig N Jenne; Kendall C Stover; Bret R Sellman; Paul Kubes
Journal:  Cell Host Microbe       Date:  2018-07-19       Impact factor: 21.023

8.  Mouse model of Gram-negative prosthetic joint infection reveals therapeutic targets.

Authors:  John M Thompson; Robert J Miller; Alyssa G Ashbaugh; Carly A Dillen; Julie E Pickett; Yu Wang; Roger V Ortines; Robert S Sterling; Kevin P Francis; Nicholas M Bernthal; Taylor S Cohen; Christine Tkaczyk; Li Yu; C Kendall Stover; Antonio DiGiandomenico; Bret R Sellman; Daniel Lj Thorek; Lloyd S Miller
Journal:  JCI Insight       Date:  2018-09-06

9.  Pseudomonas aeruginosa ExsA Regulates a Metalloprotease, ImpA, That Inhibits Phagocytosis of Macrophages.

Authors:  Zhenyang Tian; Sen Cheng; Bin Xia; Yongxin Jin; Fang Bai; Zhihui Cheng; Shouguang Jin; Xiaoyun Liu; Weihui Wu
Journal:  Infect Immun       Date:  2019-11-18       Impact factor: 3.441

10.  Pseudomonas aeruginosa Ventilator-Associated Pneumonia Rabbit Model for Preclinical Drug Development.

Authors:  Nhu T Q Nguyen; Emmanuelle Gras; Nguyen D Tran; Nhi N Y Nguyen; Hanh T H Lam; William J Weiss; Thien N M Doan; Binh An Diep
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.